Pharmaceutical

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing...

T-knife Therapeutics Announces Four Presentations at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN FRANCISCO and BERLIN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing...

Scilex Holding Company Submits a Request to the Securities and Exchange Commission to Withdraw its Registration Statement on Form S-1 (File No. 333-271401)

PALO ALTO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating...

Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting

Abstract titles to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting were released publicly today at...

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC annual meetingCompany to present interim...

Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder

Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy

– Everads' next generation suprachoroidal delivery technology enables targeted drug delivery to the retina, which Kriya intends to use for...

Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate

Updated results from the BCMA/CD19 dual-targeted GC012F, including longer-term follow-up and three additional patients, presented at the International Myeloma Society...

Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents

IBA finalizes contract with Medtechnica Ltd for two Proteus®ONE proton therapy solutions at the Tel Aviv Sourasky Medical Center in Israel  

Louvain-La-Neuve, Belgium, September 27, 2023 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading...

Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023

WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology...

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)

Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSDROCKAWAY, N.J., Sept. 27, 2023 (GLOBE...

ZyVersa Therapeutics’ CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases

Mr. Glover will also serve as a judge in BioPitch competition for life science companies seeking seed and early-stage investment.ZyVersa...

error: Content is protected !!